drugset / Trial / NCT00215657
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
Timeline
- Start
- 2003-03
- Primary completion
- 2006-03
- Completion
- 2006-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 120 mg | — |
| Subject | Degarelix | Other / unclassified | 160 mg | — |
| Subject | Degarelix | Other / unclassified | 200 mg | — |
| Subject | Degarelix | Other / unclassified | 240 mg | — |
| Subject | Degarelix | Other / unclassified | 320 mg | — |